Distinct Behaviour of Sorafenib in Experimental Cachexia-Inducing Tumours: The Role of STAT3

Inhibition of JAK-STAT signaling stimulates adult satellite cell function

(2014) Feodor D Price et al.   NATURE MEDICINE

STAT3 signaling controls satellite cell expansion and skeletal muscle repair

(2014) Matthew Timothy Tierney et al.   NATURE MEDICINE

Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin-blocked mdx mice

(2013) Juha J. Hulmi et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Mechanisms regulating skeletal muscle growth and atrophy

(2013) Stefano Schiaffino et al.   FEBS Journal

NF-κB–mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia

(2013) Wei A. He et al.   JOURNAL OF CLINICAL INVESTIGATION

Importance of functional and metabolic impairments in the characterization of the C-26 murine model of cancer cachexia

(2012) K. T. Murphy et al.   Disease Models & Mechanisms

Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity

(2011) Carla MM Prado et al.   CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE

A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: Evaluating the impact on metabolic and inflammatory profiles and quality of life

(2011) Antonio Macciò et al.   GYNECOLOGIC ONCOLOGY

STAT3 Activation in Skeletal Muscle Links Muscle Wasting and the Acute Phase Response in Cancer Cachexia

(2011) Andrea Bonetto et al.   PLoS One

Adipose Triglyceride Lipase Contributes to Cancer-Associated Cachexia

(2011) S. K. Das et al.   SCIENCE

Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance

(2011) Sílvia Busquets et al.   Journal of Cachexia Sarcopenia and Muscle

Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival

(2010) Xiaolan Zhou et al.   CELL

Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”

(2010) M. Muscaritoli et al.   CLINICAL NUTRITION

Association of Skeletal Muscle Wasting With Treatment With Sorafenib in Patients With Advanced Renal Cell Carcinoma: Results From a Placebo-Controlled Study

(2010) Sami Antoun et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3

(2010) Fan Yang et al.   MOLECULAR CANCER THERAPEUTICS

Muscle Wasting and Impaired Myogenesis in Tumor Bearing Mice Are Prevented by ERK Inhibition

(2010) Fabio Penna et al.   PLoS One

Muscle atrophy in experimental cancer cachexia: Is the IGF-1 signaling pathway involved?

(2009) Fabio Penna et al.   INTERNATIONAL JOURNAL OF CANCER

The role of cytokines in cancer cachexia

(2009) Josep M Argilés et al.   Current Opinion in Supportive and Palliative Care

Cachexia: A new definition

(2008) William J. Evans et al.   CLINICAL NUTRITION

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE